Confronto

CagriSema vs. Maridebart Cafraglutide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	CagriSema	Maridebart Cafraglutide
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

CagriSema

Voce completa →

Maridebart Cafraglutide

Voce completa →

Frequently asked questions

What is the difference between CagriSema and Maridebart Cafraglutide?: CagriSema is classified as "Metabolico", while Maridebart Cafraglutide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Maridebart Cafraglutide?: The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Maridebart Cafraglutide in Germany and the United States?: Germania: CagriSema — Non approvato, Maridebart Cafraglutide — Non approvato. Stati Uniti: CagriSema — Non approvato, Maridebart Cafraglutide — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Maridebart Cafraglutide

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between CagriSema and Maridebart Cafraglutide?

CagriSema is classified as "Metabolico", while Maridebart Cafraglutide is classified as "Metabolico". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Maridebart Cafraglutide?

The highest available evidence level is "RCT sull'uomo" for CagriSema and "RCT sull'uomo" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Maridebart Cafraglutide in Germany and the United States?

Germania: CagriSema — Non approvato, Maridebart Cafraglutide — Non approvato. Stati Uniti: CagriSema — Non approvato, Maridebart Cafraglutide — Non approvato. These are factual summaries with source and review date on the individual pages.